By Reuters Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering 1.5 milligram and 4 mg doses at $149 per month for self-paying patients in an intensely competitive weight-loss drug market. The pill was approved by the Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly. Lilly has previously said it expects a decision in March. Novo’s pill will also be sold in 9 mg and a higher long-term dose of 25 mg. The two higher doses will be priced at
The post The Wegovy weight loss pill is now available in U.S. appeared first on HBCU News.
